Lorlatinib – Induced pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Lorlatinib – Induced pulmonary arterial hypertension

Published:2018-06 Issue: Volume:120 Page:60-61
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Chabrol Alexandre,Mayenga Marie,Hamid Abdul Momen,Friard Sylvie,Salvator Hélène,Doubre Hélèe,Fraboulet Séverine,Metivier Anne-Cécile,Catherinot Emilie,Rivaud Elisabeth,Chaumais Marie Camille,Montani David,Couderc Louis Jean,Tcherakian Colas^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference6 articles.

1. Scientific advances in lung cancer;Tsao;J. Thorac. Oncol.,2015

2. MA07. 11 safety and efficacy of lorlatinib (PF-06463922) in patients with advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC);Felip;J. Thorac. Oncol.,2017

3. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib;Shah;Am. J. Hematol.,2015

4. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study;Weatherald;Eur. Respir. J.,2017

5. Imatinib in pulmonary arterial hypertension: c-Kit inhibition;Farhan;Pulm Circ.,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system;Frontiers in Pharmacology;2024-06-05

2. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events;Future Oncology;2023-09

3. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS);ESMO Open;2021-12

4. Pharmacology and pharmacovigilance of protein kinase inhibitors;Therapies;2021-11

5. Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database;European Respiratory Journal;2021-09-29